ONC206 + ONC206: Dose 1 + ONC206: Dose 2
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Pheochromocytoma and Paraganglioma
Conditions
Advanced Pheochromocytoma and Paraganglioma, PCPG
Trial Timeline
Jan 2, 2026 → Dec 15, 2028
NCT ID
NCT07282587About ONC206 + ONC206: Dose 1 + ONC206: Dose 2
ONC206 + ONC206: Dose 1 + ONC206: Dose 2 is a phase 2 stage product being developed by Jazz Pharmaceuticals for Advanced Pheochromocytoma and Paraganglioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07282587. Target conditions include Advanced Pheochromocytoma and Paraganglioma, PCPG.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07282587 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Pheochromocytoma and Paraganglioma